Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Characterization of an anti-fetal AChR monoclonal antibody isolated from a myasthenia gravis patient

  • Saxena, Abhishek
  • Stevens, Jo|||0000-0001-5737-7325
  • Cetin, Hakan
  • Koneczny, Inga
  • Webster, Richard
  • Lazaridis, Konstantinos
  • Tzartos, Socrates
  • Vrolix, Kathleen
  • Nogales, Gisela|||0000-0002-7414-212X
  • Machiels, Barbie
  • Molenaar, Peter C.
  • Damoiseaux, Jan
  • De Baets, Marc H.
  • Simon-Keller, Katja|||0000-0003-2340-8765
  • Marx, Alexander
  • Vincent, Angela|||0000-0003-2395-8695
  • Losen, Mario|||0000-0002-9761-0002
  • Martinez-Martinez, Pilar
We report here the sequence and functional characterization of a recombinantly expressed., autoantibody (mAb 131) previously isolated from a myasthenia gravis patient by immortalization of thymic B cells using Epstein-Barr virus and TLR9 activation. The antibody is characterized by a high degree of somatic mutations as well as a 6 amino acid insertion within the VHCDR2. The recombinant mAb 131 is specific for the γ-subunit of the fetal AChR to which it bound with sub-nanomolar apparent affinity, and detected the presence of fetal AChR on a number of rhabdomyosarcoma cell lines. Mab 131 blocked one of the two α-bungarotoxin binding sites on the fetal AChR, and partially blocked the binding of an antibody (mAb 637) to the α-subunit of the AChR, suggesting that both antibodies bind at or near one ACh binding site at the α/γ subunit interface. However, mAb 131 did not reduce fetal AChR ion channel currents in electrophysiological experiments. These results indicate that mAb 131, although generated from an MG patient, is unlikely to be pathogenic and may make it a potentially useful reagent for studies of myasthenia gravis, rhabdomyosarcoma and arthrogryposis multiplex congenita which can be caused by fetal-specific AChR-blocking autoantibodies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Low survival rate and muscle fiber-dependent aging effects in the McArdle disease mouse model

  • Real-Martinez, A.
  • Brull, Astrid|||0000-0002-3012-451X
  • Huerta, Jordi|||0000-0002-9908-8051
  • Tarrasó, G.
  • Lucia, Alejandro|||0000-0002-3025-2060
  • Martin, M. A.
  • Arenas, Joaquín|||0000-0002-2877-5049
  • Andreu, A. L.
  • Nogales, Gisela|||0000-0002-7414-212X
  • Vissing, John|||0000-0001-6144-8544
  • Krag, Thomas|||0000-0001-9330-668X
  • Luna Salva, Noemí de|||0000-0002-4342-794X
  • Pinós Figueras, Tomàs|||0000-0002-4379-0917
McArdle disease is an autosomal recessive disorder caused by the absence of the muscle glycogen phosphorylase, which leads to impairment of glycogen breakdown. The McArdle mouse, a model heavily affected by glycogen accumulation and exercise intolerance, was used to characterize disease progression at three different ages. The molecular and histopathological consequences of the disease were analyzed in five different hind-limb muscles (soleus, extensor digitorum longus, tibialis anterior, gastrocnemius and quadriceps) of young (8-week-old), adult (35-week-old) and old (70-week-old) mice. We found that McArdle mice have a high perinatal and post-weaning mortality. We also observed a progressive muscle degeneration, fibrosis and inflammation process that was not associated with an increase in muscle glycogen content during aging. Additionally, this progressive degeneration varied among muscle and fiber types. Finally, the lack of glycogen content increase was associated with the inactivation of glycogen synthase and not with compensatory expression of the Pygl and/or Pygb genes in mature muscle.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Three-dimensional imaging in myotonic dystrophy type 1

  • Ballester-Lopez, Alfonsina|||0000-0002-8922-1664
  • Núñez-Manchón, Judit|||0000-0001-5154-1454
  • Koehorst, Emma
  • Linares-Pardo, Ian
  • Almendrote, Míriam|||0000-0003-0212-275X
  • Lucente, Giuseppe|||0000-0003-1120-9136
  • Guanyabens Busca, Nicolau|||0000-0002-2074-2744
  • Lopez-Osias, Marta
  • Suárez-Mesa, Adrián
  • Hanick, Shaliza Ann
  • Chojnacki, Jakub|||0000-0002-4457-8096
  • Lucia, Alejandro|||0000-0002-3025-2060
  • Pintos-Morell, Guillem|||0000-0002-9347-2386
  • Coll-Cantí, Jaume|||0000-0001-7128-1186
  • Martínez-Piñeiro, Alicia|||0000-0003-1988-606X
  • Ramos-Fransi, Alba|||0000-0002-4114-4575
  • Nogales, Gisela|||0000-0002-7414-212X
We aimed to determine whether 3D imaging reconstruction allows identifying molecular:clinical associations in myotonic dystrophy type 1 (DM1). We obtained myoblasts from 6 patients with DM1 and 6 controls. We measured cytosine-thymine-guanine (CTG) expansion and detected RNA foci and muscleblind like 1 (MBNL1) through 3D reconstruction. We studied dystrophia myotonica protein kinase (DMPK) expression and splicing alterations of MBNL1, insulin receptor, and sarcoplasmic reticulum Ca(2+)-ATPase 1. Three-dimensional analysis showed that RNA foci (nuclear and/or cytoplasmic) were present in 45%-100% of DM1-derived myoblasts we studied (range: 0-6 foci per cell). RNA foci represented <0.6% of the total myoblast nuclear volume. CTG expansion size was associated with the number of RNA foci per myoblast (r = 0.876 [95% confidence interval 0.222-0.986]) as well as with the number of cytoplasmic RNA foci (r = 0.943 [0.559-0.994]). Although MBNL1 colocalized with RNA foci in all DM1 myoblast cell lines, colocalization only accounted for 1% of total MBNL1 expression, with the absence of DM1 alternative splicing patterns. The number of RNA foci was associated with DMPK expression (r = 0.967 [0.079-0.999]). On the other hand, the number of cytoplasmic RNA foci was correlated with the age at disease onset (r = -0.818 [-0.979 to 0.019]). CTG expansion size modulates RNA foci number in myoblasts derived from patients with DM1. MBNL1 sequestration plays only a minor role in the pathobiology of the disease in these cells. Higher number of cytoplasmic RNA foci is related to an early onset of the disease, a finding that should be corroborated in future studies.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Sex Differences and the Influence of an Active Lifestyle on Adiposity in Patients with McArdle Disease

  • Rodríguez-Gómez, Irene|||0000-0002-1622-7109
  • Santalla, Alfredo|||0000-0001-9418-0564
  • Díez Bermejo, Jorge
  • Munguía-Izquierdo, Diego|||0000-0001-7817-747X
  • Alegre, Luis M.|||0000-0002-4502-9275
  • Nogales, Gisela|||0000-0002-7414-212X
  • Arenas, Joaquín|||0000-0002-2877-5049
  • Martín, Miguel A.|||0000-0003-4741-772X
  • Lucia, Alejandro|||0000-0002-3025-2060
  • Ara, Ignacio|||0000-0002-2854-6684
McArdle disease (glycogenosis-V) is associated with exercise intolerance, however, how it affects an important marker of cardiometabolic health as it is adiposity remains unknown. We evaluated the association between physical activity (PA) and adiposity in patients with McArdle disease. We assessed 199 adults of both sexes (51 McArdle patients (36 ± 11 years) and 148 healthy controls (35 ± 10 years)). Body fat (BF) was determined using dual-energy X-ray absorptiometry (DXA) method and each patient's PA was assessed with the International PA Questionnaire (IPAQ). Although body mass index values did not differ between patients and controls, McArdle patients had significantly higher values of BF in all body regions (p < 0.05) and higher risk of suffering obesity (odds ratio (OR): 2.54, 95% confidence interval (95% CI): 1.32-4.88). Male patients had higher BF and obesity risk (OR: 3.69, 95% CI: 1.46-9.34) than their sex-matched controls, but no differences were found within the female sex (p < 0.05). In turn, active female patients had lower trunk BF than their inactive peers (p < 0.05). Males with McArdle seem to have adiposity problems and a higher risk of developing obesity than people without the condition, while female patients show similar or even better levels in the trunk region with an active lifestyle. Therefore, special attention should be given to decrease adiposity and reduce obesity risk in males with McArdle disease.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Need for Establishing a Universal CTG Sizing Method in Myotonic Dystrophy Type 1

  • Ballester-Lopez, Alfonsina|||0000-0002-8922-1664
  • Linares-Pardo, Ian
  • Koehorst, Emma
  • Núñez-Manchón, Judit|||0000-0001-5154-1454
  • Pintos-Morell, Guillem|||0000-0002-9347-2386
  • Coll-Cantí, Jaume|||0000-0001-7128-1186
  • Almendrote, Míriam|||0000-0003-0212-275X
  • Lucente, Giuseppe|||0000-0003-1120-9136
  • Arbex, Andrea|||0000-0002-3741-4755
  • Magaña, Jonathan J.|||0000-0003-4399-4618
  • Murillo-Melo, Nadia M.
  • Lucia, Alejandro|||0000-0002-3025-2060
  • Monckton, Darren G.|||0000-0002-8298-8264
  • Cumming, Sarah A.|||0000-0002-0201-3660
  • Ramos-Fransi, Alba|||0000-0002-4114-4575
  • Martínez-Piñeiro, Alicia|||0000-0003-1988-606X
  • Nogales, Gisela|||0000-0002-7414-212X
The number of cytosine-thymine-guanine (CTG) repeats ('CTG expansion size') in the 3'untranslated region (UTR) region of the dystrophia myotonica -protein kinase (DMPK) gene is a hallmark of myotonic dystrophy type 1 (DM1), which has been related to age of disease onset and clinical severity. However, accurate determination of CTG expansion size is challenging due to its characteristic instability. We compared five different approaches (heat pulse extension polymerase chain reaction [PCR], long PCR-Southern blot [with three different primers sets-1, 2 and 3] and small pool [SP]-PCR) to estimate CTG expansion size in the progenitor allele as well as the most abundant CTG expansion size, in 15 patients with DM1. Our results indicated variability between the methods (although we found no overall differences between long PCR 1 and 2 and SP-PCR, respectively). While keeping in mind the limited sample size of our patient cohort, SP-PCR appeared as the most suitable technique, with an inverse significant correlation found between CTG expansion size of the progenitor allele, as determined by this method, and age of disease onset (r = -0.734, p = 0.016). Yet, in light of the variability of the results obtained with the different methods, we propose that an international agreement is needed to determine which is the most suitable method for assessing CTG expansion size in DM1
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Preliminary Findings on CTG Expansion Determination in Different Tissues from Patients with Myotonic Dystrophy Type 1

  • Ballester-Lopez, Alfonsina|||0000-0002-8922-1664
  • Koehorst, Emma
  • Linares-Pardo, Ian
  • Núñez-Manchón, Judit|||0000-0001-5154-1454
  • Almendrote, Míriam|||0000-0003-0212-275X
  • Lucente, Giuseppe|||0000-0003-1120-9136
  • Arbex, Andrea|||0000-0002-3741-4755
  • Puente-Alonso, Carles
  • Lucia, Alejandro|||0000-0002-3025-2060
  • Monckton, Darren G.|||0000-0002-8298-8264
  • Cumming, Sarah A.|||0000-0002-0201-3660
  • Pintos-Morell, Guillem|||0000-0002-9347-2386
  • Coll-Cantí, Jaume|||0000-0001-7128-1186
  • Ramos-Fransi, Alba|||0000-0002-4114-4575
  • Martínez-Piñeiro, Alicia|||0000-0003-1988-606X
  • Nogales, Gisela|||0000-0002-7414-212X
Myotonic Dystrophy type 1 (DM1) is characterized by a high genetic and clinical variability. Determination of the genetic variability in DM1 might help to determine whether there is an association between CTG (Cytosine-Thymine-Guanine) expansion and the clinical manifestations of this condition. We studied the variability of the CTG expansion (progenitor, mode, and longest allele, respectively, and genetic instability) in three tissues (blood, muscle, and tissue) from eight patients with DM1. We also studied the association of genetic data with the patients' clinical characteristics. Although genetic instability was confirmed in all the tissues that we studied, our results suggest that CTG expansion is larger in muscle and skin cells compared with peripheral blood leukocytes. While keeping in mind that more research is needed in larger cohorts, we have provided preliminary evidence suggesting that the estimated progenitor CTG size in muscle could be potentially used as an indicator of age of disease onset and muscle function impairment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Biomarker Potential of miRNAs in Myotonic Dystrophy Type I

  • Koehorst, Emma
  • Ballester-Lopez, Alfonsina|||0000-0002-8922-1664
  • Arechavala-Gomeza, Virginia|||0000-0001-7703-3255
  • Martínez-Piñeiro, Alicia|||0000-0003-1988-606X
  • Nogales, Gisela|||0000-0002-7414-212X
MicroRNAs (miRNAs) are mostly known for their gene regulation properties, but they also play an important role in intercellular signaling. This means that they can be found in bodily fluids, giving them excellent biomarker potential. Myotonic Dystrophy type I (DM1) is the most frequent autosomal dominant muscle dystrophy in adults, with an estimated prevalence of 1:8000. DM1 symptoms include muscle weakness, myotonia, respiratory failure, cardiac conduction defects, cataracts, and endocrine disturbances. Patients display heterogeneity in both age of onset and disease manifestation. No treatment or cure currently exists for DM1, which shows the necessity for a biomarker that can predict disease progression, providing the opportunity to implement preventative measures before symptoms arise. In the past two decades, extensive research has been conducted in the miRNA expression profiles of DM1 patients and their biomarker potential. Here we review the current state of the field with a tissue-specific focus, given the multi-systemic nature of DM1 and the intracellular signaling role of miRNAs.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Genotypic and phenotypic features of all Spanish patients with McArdle disease, a 2016 update

  • Santalla, Alfredo|||0000-0001-9418-0564
  • Nogales, Gisela|||0000-0002-7414-212X
  • Encinar, Alberto Blazquez
  • Vieitez, Irene
  • González-Quintana, Adrian
  • Serrano-Lorenzo, Pablo|||0000-0002-5661-7574
  • Consuegra-García, Inés
  • Asensio-Peña, Sara|||0000-0002-2048-5899
  • Ballester-Lopez, Alfonsina|||0000-0002-8922-1664
  • Pintos-Morell, Guillem|||0000-0002-9347-2386
  • Coll-Cantí, Jaume|||0000-0001-7128-1186
  • Pareja-Galeano, Helios
  • Díez Bermejo, Jorge
  • Pérez Ruiz, Margarita|||0000-0001-7240-2082
  • Andreu Périz, Antoni Lluís
  • Pinós Figueras, Tomàs|||0000-0002-4379-0917
  • Arenas, Joaquín|||0000-0002-2877-5049
  • Martín, Miguel A.|||0000-0003-4741-772X
  • Lucia, Alejandro|||0000-0002-3025-2060
We recently described the genotype/phenotype features of all Spanish patients diagnosed with McArdle disease as of January 2011 (n = 239, prevalence of ~1/167,000) (J Neurol Neurosurg Psychiatry 2012;83:322-8). Several caveats were however identified suggesting that the prevalence of the disease is actually higher. We have now updated main genotype/phenotype data, as well as potential associations within/between them, of all Spanish individuals currently diagnosed with McArdle disease (December 2016). Ninety-four new patients (all Caucasian) have been diagnosed, yielding a prevalence of ~1/139,543 individuals. Around 55% of the mutated alleles have the commonest PYGM pathogenic mutation p.R50X, whereas p.W798R and p.G205S account for 10 and 9% of the allelic variants, respectively. Seven new mutations were identified: p.H35R, p.R70C, p.R94Q, p.L132WfsX163, p.Q176P, p.R576Q, and c.244-3_244-2CA. Almost all patients show exercise intolerance, the second wind phenomenon and high serum creatine kinase activity. There is, however, heterogeneity in clinical severity, with 8% of patients being asymptomatic during normal daily life, and 21% showing limitations during daily activities and fixed muscle weakness. A major remaining challenge is one of diagnosis, which is often delayed until the third decade of life in 72% of new patients despite the vast majority (86%) reporting symptoms before 20 years. An important development is the growing proportion of those reporting a 4-year improvement in disease severity (now 34%) and following an active lifestyle (50%). Physically active patients are more likely to report an improvement after a 4-year period in the clinical course of the disease than their inactive peers (odds ratio: 13.98; 95% confidence interval: 5.6, 34.9; p < 0.001). Peak oxygen uptake is also higher in the former (20.7 ± 6.0 vs. 16.8 ± 5.3 mL/kg/min, p = 0.0013). Finally, there is no association between PYGM genotype and phenotype manifestation of the disease. The reported prevalence of McArdle disease grows exponentially despite frequent, long delays in genetic diagnosis, suggesting that many patients remain undiagnosed. Until a genetic cure is available (which is not predicted in the near future), current epidemiologic data support that adoption of an active lifestyle is the best medicine for these patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Characterization of RAN Translation and Antisense Transcription in Primary Cell Cultures of Patients with Myotonic Dystrophy Type 1

  • Koehorst, Emma
  • Núñez-Manchón, Judit|||0000-0001-5154-1454
  • Ballester-Lopez, Alfonsina|||0000-0002-8922-1664
  • Almendrote, Míriam|||0000-0003-0212-275X
  • Lucente, Giuseppe|||0000-0003-1120-9136
  • Arbex, Andrea|||0000-0002-3741-4755
  • Chojnacki, Jakub|||0000-0002-4457-8096
  • Vázquez-Manrique, Rafael P.|||0000-0002-1594-0033
  • Gómez-Escribano, Ana Pilar|||0000-0003-4391-5932
  • Pintos-Morell, Guillem|||0000-0002-9347-2386
  • Coll-Cantí, Jaume|||0000-0001-7128-1186
  • Ramos-Fransi, Alba|||0000-0002-4114-4575
  • Martínez-Piñeiro, Alicia|||0000-0003-1988-606X
  • Suelves Esteban, Mònica|||0000-0001-7095-5804
  • Nogales, Gisela|||0000-0002-7414-212X
Myotonic Dystrophy type 1 (DM1) is a muscular dystrophy with a multi-systemic nature. It was one of the first diseases in which repeat associated non-ATG (RAN) translation was described in 2011, but has not been further explored since. In order to enhance our knowledge of RAN translation in DM1, we decided to study the presence of DM1 antisense (DM1-AS) transcripts (the origin of the polyglutamine (polyGln) RAN protein) using RT-PCR and FISH, and that of RAN translation via immunoblotting and immunofluorescence in distinct DM1 primary cell cultures, e.g., myoblasts, skin fibroblasts and lymphoblastoids, from ten patients. DM1-AS transcripts were found in all DM1 cells, with a lower expression in patients compared to controls. Antisense RNA foci were found in the nuclei and cytoplasm of a subset of DM1 cells. The polyGln RAN protein was undetectable in all three cell types with both approaches. Immunoblots revealed a 42 kD polyGln containing protein, which was most likely the TATA-box-binding protein. Immunofluorescence revealed a cytoplasmic aggregate, which co-localized with the Golgi apparatus. Taken together, DM1-AS transcript levels were lower in patients compared to controls and a small portion of the transcripts included the expanded repeat. However, RAN translation was not present in patient-derived DM1 cells, or was in undetectable quantities for the available methods.